Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Core Insights - AnaptysBio, Inc. will host a virtual investor event on its CD122 antagonist, ANB033, on October 14, 2025 [1][2] - The event will feature Dr. Joseph A. Murray from the Mayo Clinic and members of Anaptys management, followed by a Q&A session [2] - A live webcast of the presentation will be available on Anaptys' investor website, with a replay accessible afterward [3] About ANB033 - ANB033 is a potentially best-in-class CD122 antagonist targeting CD122, which is crucial for the maintenance and survival of certain immune cells [4] - The drug is currently in a Phase 1b trial for celiac disease, marking its initial indication [4] About AnaptysBio - AnaptysBio is focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [5] - The company's lead program, rosnilimab, has completed a Phase 2b trial for rheumatoid arthritis and is in a Phase 2 trial for ulcerative colitis [5] - Anaptys' pipeline includes ANB033 and ANB101, both in Phase 1 trials, and has successfully out-licensed multiple therapeutic antibodies [5]